Alps Advisors Inc. bought a new position in shares of ESSA Pharma Inc. (NASDAQ:EPIX – Get Rating) (TSE:EPI) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 26,140 shares of the company’s stock, valued at approximately $82,000. Alps Advisors Inc. owned about 0.06% of ESSA Pharma at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in EPIX. Prospera Financial Services Inc purchased a new position in shares of ESSA Pharma during the first quarter worth $47,000. Bank of America Corp DE raised its holdings in shares of ESSA Pharma by 41.7% during the first quarter. Bank of America Corp DE now owns 11,614 shares of the company’s stock worth $72,000 after purchasing an additional 3,420 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of ESSA Pharma during the first quarter worth $154,000. Raymond James & Associates purchased a new position in shares of ESSA Pharma during the first quarter worth $251,000. Finally, Qube Research & Technologies Ltd purchased a new position in shares of ESSA Pharma during the first quarter worth $295,000.
ESSA Pharma Stock Performance
EPIX stock opened at $3.11 on Thursday. The firm has a market cap of $137.07 million, a PE ratio of -3.62 and a beta of 2.05. The firm’s fifty day moving average is $2.57 and its 200 day moving average is $3.30. ESSA Pharma Inc. has a one year low of $1.40 and a one year high of $14.88.
Insider Activity at ESSA Pharma
About ESSA Pharma
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer.
- Get a free copy of the StockNews.com research report on ESSA Pharma (EPIX)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.